ICICI Securities Ltd | Retail Equity Research Revenues grew 12.1% YoY to | 3736.5 crore (I-direct estimate: | 3577 crore) on the back of 1) gSuboxone windfall, 2) lower base in the domestic formulations and 3) strong revival in Russia. US revenues grew 6.4% YoY to | 1590 crore (I-direct estimate: | 1517 crore) on the back of gSuboxone (anti-opioid addiction) launch EBITDA margins improved to 20.6% (I-direct estimate: 17.3%) from 9.7% in Q1FY18 and 17.3% in Q4FY18 mainly due to sharp reduction...